KPTI

Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million

Karyopharm: Why Is It Down, And What Should Take It Back Up

Karyopharm Stock Is Trading Higher On Updated Eltanexor Data In Patients With Blood Disorder

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress

Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS

Karyopharm Announces Key Changes to Its Commercial Leadership Team

Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma